BR112019000118A2 - proteína sdss1 natural inovadora, sequência de polipeptídeos, proteína de fusão, complexo, nucleotídeo, célula, sistema de expressão, fármaco de alvejamento principal da proteína sdss1 e aplicação - Google Patents

proteína sdss1 natural inovadora, sequência de polipeptídeos, proteína de fusão, complexo, nucleotídeo, célula, sistema de expressão, fármaco de alvejamento principal da proteína sdss1 e aplicação

Info

Publication number
BR112019000118A2
BR112019000118A2 BR112019000118A BR112019000118A BR112019000118A2 BR 112019000118 A2 BR112019000118 A2 BR 112019000118A2 BR 112019000118 A BR112019000118 A BR 112019000118A BR 112019000118 A BR112019000118 A BR 112019000118A BR 112019000118 A2 BR112019000118 A2 BR 112019000118A2
Authority
BR
Brazil
Prior art keywords
protein
sdss1
nucleotide
complex
cell
Prior art date
Application number
BR112019000118A
Other languages
English (en)
Inventor
Wan Jia
Fu Jingpeng
Zhang Yinghao
Original Assignee
Shanghai Clear Fluid Biomedical Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Clear Fluid Biomedical Science Co Ltd filed Critical Shanghai Clear Fluid Biomedical Science Co Ltd
Publication of BR112019000118A2 publication Critical patent/BR112019000118A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

trata-se de uma proteína secretora sdss1 de um primata superior. a proteína pode ser detectada em soro sanguíneo humano e fluido cerebrospinal. a proteína sdss1 pode se ligar, sob condições não enzimáticas, a uma proteína oxidada para formar um polímero ou se ligar a um polipeptídeo aß para reduzir a formação de um oligômero aß. na cultura, a proteína sdss1 pode blindar contra citotoxicidade induzida por uma proteína oxidada, oligômero aß, oligômero de amilina ou proteína glicosilada. a proteínas sdss1 pode significativamente estender a sobrevivência de um modelo de camundongo com progéria. a proteína pode ser usada para prevenir ou tratar uma doença causada pela acumulação de uma proteína oxidada, glicoproteína, proteína aß ou amilina ou pela geração ou acúmulo de outra proteína patogênica com uma propriedade similar.
BR112019000118A 2016-07-04 2017-06-29 proteína sdss1 natural inovadora, sequência de polipeptídeos, proteína de fusão, complexo, nucleotídeo, célula, sistema de expressão, fármaco de alvejamento principal da proteína sdss1 e aplicação BR112019000118A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610519038.9A CN107573412B (zh) 2016-07-04 2016-07-04 一种新型天然蛋白及其应用
PCT/CN2017/090785 WO2018006750A1 (zh) 2016-07-04 2017-06-29 一种新型天然蛋白及其应用

Publications (1)

Publication Number Publication Date
BR112019000118A2 true BR112019000118A2 (pt) 2019-07-09

Family

ID=60911986

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000118A BR112019000118A2 (pt) 2016-07-04 2017-06-29 proteína sdss1 natural inovadora, sequência de polipeptídeos, proteína de fusão, complexo, nucleotídeo, célula, sistema de expressão, fármaco de alvejamento principal da proteína sdss1 e aplicação

Country Status (17)

Country Link
US (3) US10815282B2 (pt)
EP (1) EP3444270A4 (pt)
JP (5) JP2019513023A (pt)
KR (2) KR102602486B1 (pt)
CN (2) CN113150105B (pt)
AU (3) AU2017293023B2 (pt)
BR (1) BR112019000118A2 (pt)
CA (1) CA3029458A1 (pt)
CL (1) CL2019000012A1 (pt)
CO (1) CO2019000235A2 (pt)
EA (1) EA201990179A1 (pt)
IL (2) IL301949A (pt)
MX (1) MX2019000192A (pt)
PH (1) PH12018550214A1 (pt)
SG (1) SG11201811555VA (pt)
WO (1) WO2018006750A1 (pt)
ZA (1) ZA201900209B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113150105B (zh) 2016-07-04 2024-02-20 上海普佑生物医药有限公司 一种新型天然蛋白及其应用
CN109913483A (zh) * 2017-12-12 2019-06-21 上海清流生物医药科技有限公司 一种蛋白药物的发酵生产工艺
CN109985230B (zh) * 2018-01-02 2023-10-17 上海普佑生物医药有限公司 一种蛋白在制备预防和治疗肾病药物中的应用
CN109985231A (zh) * 2018-01-02 2019-07-09 上海清流生物医药科技有限公司 一种蛋白在制备预防和治疗痴呆症的药物中的应用
CN110004105B (zh) * 2018-01-05 2023-09-29 上海普佑生物医药有限公司 一种蛋白在细胞培养中的应用
CN110302362B (zh) * 2018-03-20 2024-04-05 上海普佑生物医药有限公司 一种蛋白在制备预防和治疗糖尿病并发症的药物中的应用
CN110882378A (zh) * 2018-09-10 2020-03-17 上海清流生物医药科技有限公司 一种蛋白在制备预防和治疗动脉粥样硬化及并发症药物的应用
CN118510793A (zh) * 2021-09-15 2024-08-16 上海普佑生物医药有限公司 新型多肽
CN115287276A (zh) * 2022-03-07 2022-11-04 兰州大学 Sem1蛋白、表达sem1蛋白工程化益生菌在制备治疗和/或预防心脏病药物中的应用
WO2024056028A1 (en) * 2022-09-15 2024-03-21 Shanghai Puyou Biochemical Co., Ltd. Analgesic polypeptide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1947112B1 (en) * 1999-04-09 2012-05-16 Heska Corporation Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof
JP2004121445A (ja) * 2002-10-01 2004-04-22 Akira Sakai 酸化ストレス消去材、それを有する透析液循環回路及び酸化ストレス消去法
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US9134318B2 (en) * 2009-12-11 2015-09-15 Purdue Research Foundation Detection of oxidized polypeptides
CN102755317A (zh) * 2011-04-28 2012-10-31 中国人民解放军军事医学科学院放射与辐射医学研究所 一类2-吲哚酮衍生物及其药用盐用于制备抗氧化药物的用途
CN113150105B (zh) 2016-07-04 2024-02-20 上海普佑生物医药有限公司 一种新型天然蛋白及其应用

Also Published As

Publication number Publication date
JP2020114833A (ja) 2020-07-30
MX2019000192A (es) 2019-06-20
CN113150105A (zh) 2021-07-23
JP7386923B2 (ja) 2023-11-27
CO2019000235A2 (es) 2019-02-08
IL301949A (en) 2023-06-01
JP2022101661A (ja) 2022-07-06
EA201990179A1 (ru) 2019-09-30
JP2019513023A (ja) 2019-05-23
CN113150105B (zh) 2024-02-20
WO2018006750A8 (zh) 2018-02-08
KR102602486B1 (ko) 2023-11-14
CL2019000012A1 (es) 2019-03-22
JP2022101660A (ja) 2022-07-06
JP2022101659A (ja) 2022-07-06
EP3444270A4 (en) 2019-07-31
KR20180127382A (ko) 2018-11-28
SG11201811555VA (en) 2019-01-30
US10815282B2 (en) 2020-10-27
WO2018006750A1 (zh) 2018-01-11
PH12018550214A1 (en) 2019-10-28
IL263987A (en) 2019-02-03
US20190085041A1 (en) 2019-03-21
ZA201900209B (en) 2020-08-26
CN107573412B (zh) 2021-04-27
AU2017293023B2 (en) 2020-09-17
US11198712B2 (en) 2021-12-14
IL263987B2 (en) 2023-09-01
IL263987B1 (en) 2023-05-01
AU2020233647A1 (en) 2020-10-08
US20220135631A1 (en) 2022-05-05
AU2017293023A1 (en) 2019-02-14
CA3029458A1 (en) 2018-01-11
AU2022203613A1 (en) 2022-06-16
KR20210122891A (ko) 2021-10-12
US20210009644A1 (en) 2021-01-14
CN107573412A (zh) 2018-01-12
EP3444270A1 (en) 2019-02-20
AU2022203613B2 (en) 2023-08-31
AU2020233647B2 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
BR112019000118A2 (pt) proteína sdss1 natural inovadora, sequência de polipeptídeos, proteína de fusão, complexo, nucleotídeo, célula, sistema de expressão, fármaco de alvejamento principal da proteína sdss1 e aplicação
Sato et al. High mannose-specific lectin (KAA-2) from the red alga Kappaphycus alvarezii potently inhibits influenza virus infection in a strain-independent manner
Betanzos et al. Host invasion by pathogenic amoebae: epithelial disruption by parasite proteins
Singh et al. Algal lectins as promising biomolecules for biomedical research
Superti et al. Bovine lactoferrin prevents influenza A virus infection by interfering with the fusogenic function of viral hemagglutinin
Plummer et al. A serine‐rich glycoprotein of Streptococcus sanguis mediates adhesion to platelets via GPIb
BR112015022971A2 (pt) métodos de fabricação para controlar o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
BR112016002614A8 (pt) Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
ES2663872T3 (es) Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria
Ng et al. Soluble host defense lectins in innate immunity to influenza virus
BR112012027055A8 (pt) agente estabilizante para proteínas farmacêuticas.
BR112014007484A2 (pt) molécula de ligação a antígeno de indução de resposta imune a antígeno alvo
NZ629261A (en) Pharmaceutical formulations of tnf-alpha antibodies
MX2019006633A (es) Formulaciones de anticuerpo.
CL2021002426A1 (es) Bioconjugados de antígenos polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos.
Chatterjee et al. Anti-retroviral lectins have modest effects on adherence of Trichomonas vaginalis to epithelial cells in vitro and on recovery of Tritrichomonas foetus in a mouse vaginal model
BR112016020644A8 (pt) Conjugado de um oligômero de ácido hialurônico ou um sal do mesmo, método de preparação e uso
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
BR112012018841A2 (pt) "estrutura para a redução de uma resistência ao fluxo de um corpo em um fluido"
BR112017008525A2 (pt) proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo.
Rüffer et al. Cell− Cell junctions of dermal microvascular endothelial cells contain tight and adherens junction proteins in spatial proximity
Kurguzova et al. Interconnection of antitoxic and antioxidant systems of the organism under the action of natural low molecular complex-fungidol
BR112020004935A8 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
Kurisaka et al. Role of sialic acid‐containing glycans of matrix metalloproteinase‐9 (MMP‐9) in the interaction between MMP‐9 and staphylococcal superantigen‐like protein 5
BR112018077225A2 (pt) proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2626 DE 04-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]